

# Department of Health and Human Services

## Part 1. Overview Information

<p><b>Participating Organization(s)</b></p>	<p>U.S. Food and Drug Administration (<a href="#">FDA</a>)</p> <p>The policies, guidelines, terms, and conditions stated in this announcement may differ from those used by the NIH. Where this Funding Opportunity Announcement (FOA) provides specific written guidance that may differ from the general guidance provided in the grant application form, please follow the instructions given in this FOA.</p> <p>The FDA does not follow the NIH Page Limitation Guidelines or the NIH Review Criteria. Applicants are encouraged to consult with FDA <a href="#">Agency Contacts</a> for additional information regarding page limits and the FDA Objective Review Process.  </p>
<p><b>Components of Participating Organizations</b></p>	<p>Center for Food Safety and Applied Nutrition (<a href="#">CFSAN</a>)  </p>
<p><b>Funding Opportunity Title</b></p>	<p><b>Cooperative Agreement to Support the Joint Institute for Food Safety and Applied Nutrition, JIFSAN (U19)</b></p>
<p><b>Activity Code</b></p>	<p><a href="#">U19</a> Research Program--Cooperative Agreements  </p>
<p><b>Announcement Type</b></p>	<p>Renewal  </p>
<p><b>Related Notices</b></p>	<p>None</p>
<p><b>Funding Opportunity Announcement (FOA) Number</b></p>	<p><b>RFA-FD-17-003</b>  </p>
<p><b>Companion Funding</b></p>	<p>None  </p>

<b>Opportunity</b>	
<b>Number of Applications</b>	See <a href="#">Section III. 3. Additional Information on Eligibility.</a>
<b>Catalog of Federal Domestic Assistance (CFDA) Number(s)</b>	93.103
<b>Funding Opportunity Purpose</b>	<p>The Food and Drug Administration (FDA) is announcing its intention to receive and consider a cooperative agreement with the University of Maryland, College Park (UMCP), to support the Joint Institute for Food Safety and Applied Nutrition (JIFSAN).</p> <p>The purposes of this partnership are to:</p> <ol style="list-style-type: none"> <li>1) Continue promoting the integration of applied research, education, and outreach programs that have been established between UMCP-JIFSAN and FDA to advance the scientific base for the development of sound public policy;</li> <li>2) Enhance FDA's ability to address an increasing number of critical and complex food safety and public health issues associated with foods that FDA regulates;</li> <li>3) Provide opportunities to leverage additional resources among US government agencies, academia, industry and consumers to address new and emerging issues associated with an increasingly diverse domestic and global food supply;</li> <li>4) Continue to promote a greater awareness and understanding of the critical role of regulatory science and practice among academic scientists and the pool of future scientists; and</li> <li>5) Support the FDA Food Safety Modernization Act, which emphasizes the concept of preventing food safety-related problems before they occur, and enhance FDA's efforts to partner with other nations to improve US and worldwide health.  </li> </ol>

## Key Dates

<b>Posted Date</b>	
<b>Open Date (Earliest)</b>	February 15, 2017

<b>Submission Date)</b>	
<b>Letter of Intent Due Date(s)</b>	[Not Applicable]
<b>Application Due Date(s)</b>	<p>[April 17, 2017], by 11:59 PM Eastern Time.</p> <p>Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.</p> <p>Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.</p> <p><b>Late applications will not be accepted for this FOA.</b></p>
<b>AIDS Application Due Date(s)</b>	[Not Applicable]
<b>Scientific Merit Review</b>	[May 2017]
<b>Advisory Council Review</b>	[Not Applicable]
<b>Earliest Start Date</b>	[September 2017]
<b>Expiration Date</b>	[April 18, 2017]
<b>Due Dates for E.O. 12372</b>	[Not Applicable]

### Required Application Instructions

It is critical that applicants follow the instructions in the [SF424 \(R&R\) Application Guide](#), except where instructed to do otherwise (in this FOA or in a Notice from the [NIH Guide for Grants and Contracts](#)). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in [Section IV](#). When the program-specific instructions

deviate from those in the Application Guide, follow the program-specific instructions.

**Applications that do not comply with these instructions may be delayed or not accepted for review.**

## Table of Contents

[Part 1. Overview Information](#)

[Part 2. Full Text of the Announcement](#)

[Section I. Funding Opportunity Description](#)

[Section II. Award Information](#)

[Section III. Eligibility Information](#)

[Section IV. Application and Submission Information](#)

[Section V. Application Review Information](#)

[Section VI. Award Administration Information](#)

[Section VII. Agency Contacts](#)

[Section VIII. Other Information](#)

## Part 2. Full Text of Announcement

### Section I. Funding Opportunity Description

Since 1997, FDA's partnership with UMCP-JIFSAN has been successful in developing multiple programs to support public health policy. The goal of JIFSAN is to advance sound strategies that improve public health, nutrition, and food/feed safety through three broad program areas: research, education, and outreach.

With an increasingly diverse domestic and global food supply, FDA continues to face complex food safety issues associated with products that it regulates (i.e., conventional foods; food ingredients; dietary supplements; cosmetics; animal feed, feed additives and animal drugs). FDA believes that some of these complex issues can be effectively addressed by further strengthening the available science-based programs established through JIFSAN. FDA also believes that innovative capacity-building partnerships with various sectors of stakeholders in conjunction with JIFSAN's research and training programs can further support the development of proactive approaches to the prevention of problems before they occur.

This cooperative agreement will provide continued support so that UMCP-JIFSAN can meet the following objectives:

Establish multi-institutional, multidisciplinary applied research projects to address complex food/feed safety and public health issues associated with products that FDA regulates. Applied research includes not only traditional laboratory and field research, but also epidemiological, educational, social and behavioral science.

Continue the development of mechanisms for the exchange of technical information and scientific concepts between FDA and other sectors of the international and domestic community, through workshops, short courses and symposia, and on-line resources that focus on existing and emerging complex food/feed safety and public health issues.

Continue the development and refinement of programs based on the application of the principles of risk analysis to address food/feed defense and safety issues.

Continue the design and improvement of domestic and international collaborations, which foster greater implementation of effective food safety practices.

Continue developing innovative education and outreach programs that will provide opportunities to

leverage resources among various sectors of stakeholders to address complex safety issues associated with an increasingly diverse global food/feed supply. |

See Section VIII. Other Information for award authorities and regulations.

## Section II. Award Information

<p><b>Funding Instrument</b></p>	<p>Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, FDA scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.  </p>
<p><b>Application Types Allowed</b></p>	<p>Renewal</p> <p>The <a href="#">OER Glossary</a> and the SF424 (R&amp;R) Application Guide provide details on these application types.</p>
<p><b>Funds Available and Anticipated Number of Awards</b></p>	<p>The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for four (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory awardee performance.  </p> <p>FDA/CFSAN intends to fund up to \$ 3.3 million for fiscal year 2017.  </p> <p>Allowable cost increases of up to 4.3% per annum is allowed with an estimated amount of support of up to \$ 3.91 million for the final year of the award.</p>
<p><b>Award Budget</b></p>	<p>Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect):  </p> <p>YR 01: \$ 3,300,000  YR 02: \$3,440,000  YR 03: \$ 3,590,000  YR 04: \$ 3,740,000  YR 05: \$ 3,910,000</p>
<p><b>Award Project Period</b></p>	<p>The scope of the proposed project should determine the project period. The maximum project period is five (5) years.</p>

HHS grants policies as described in the [HHS Grants Policy Statement](#) will apply to the applications

submitted and awards made in response to this FOA.

## Section III. Eligibility Information

### 1. Eligible Applicants

The following organization is eligible to apply:

The University of Maryland, College Park (UMCP), Joint Institute for Food Safety and Applied Nutrition, JIFSAN.

#### Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) **are not** eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations **are not** eligible to apply.

Foreign components, as [defined in the HHS Grants Policy Statement](#), **are** allowed.

#### Required Registrations

##### Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission.

- [Dun and Bradstreet Universal Numbering System \(DUNS\)](#) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
- System for Award Management (SAM) (formerly CCR) – Applicants must complete and maintain an active registration, **which requires renewal at least annually**. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  - [NATO Commercial and Government Entity \(NCAGE\) Code](#) – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
- eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

##### Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

##### Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for FDA support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

## 2. Cost Sharing

This FOA does not require cost sharing as defined in the [HHS Grants Policy Statement](#).

## 3. Additional Information on Eligibility

### Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The FDA will not accept duplicate or highly overlapping applications under review at the same time. This means that the FDA will not accept:

- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

## Section IV. Application and Submission Information

### 1. Requesting an Application Package

Buttons to access the online ASSIST system or to download application forms are available in [Part 1](#) of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

### 2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research Instructions for the [SF424 \(R&R\) Application Guide](#), including [Supplemental Grant Application Instructions](#) except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit [Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications](#).

### Page Limitations

All page limitations described in the SF424 Application Guide and the [Table of Page Limits](#) must be followed, with the following exceptions or additional requirements:

- For this specific FOA, the Research Strategy section is limited to 30 pages. [ ]

### Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

### SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

## **SF424 (R&R) Project/Performance Site Locations**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

## **SF424 (R&R) Other Project Information**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

## **SF424 (R&R) Senior/Key Person Profile**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

## **R&R Budget**

All instructions in the SF424 (R&R) Application Guide must be followed with the following additional instructions:

- Applications requesting multiple years of support must complete and submit a separate detailed budget breakdown and narrative justification for each year of financial support requested.
- If an applicant is requesting indirect costs as part of their budget, a copy of the most recent Federal indirect cost rate or F&A agreement must be provided as part of the application submission. This agreement should be attached to the RESEARCH & RELATED Other Project Information Component as line #12 'Other Attachments'.
- If the applicant organization has never established an indirect cost rate and/or does not have a negotiated Federal indirect cost rate agreement, a de minimis indirect cost rate of 10 percent (10%) of modified total direct costs (MTDC) will be allowed. MTDC means all direct salaries and wages, applicable fringe benefits, materials and supplies, services, travel, and subaward and subcontracts up to the first \$25,000 of each subaward or subcontract. MTDC excludes equipment, capital expenditures, charges for patient care, rental costs, tuition remission, scholarships and fellowships, participant support costs and the portion of each subaward and subcontract in excess of \$25,000. [ ]

## **R&R Subaward Budget**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

## **PHS 398 Cover Page Supplement**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

## **PHS 398 Research Plan**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]

**Resource Sharing Plan:** Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification: [ ]

- All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan. [ ]

**Appendix:** Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide. [ ]

## **PHS Inclusion Enrollment Report**

When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

## **PHS Assignment Request Form**

All instructions in the SF424 (R&R) Application Guide must be followed. [ ]



## Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the [HHS Grants Policy Statement](#), and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

## 3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

## 4. Submission Dates and Times

[Part I. Overview Information](#) contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications to [Grants.gov](#) (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the [eRA Commons](#), FDA's electronic system for grants administration. eRA Commons and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. **Late applications will not be accepted for this FOA.**

**Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.**

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

## 5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to [intergovernmental review](#).

## 6. Funding Restrictions

All FDA awards are subject to the terms and conditions, cost principles, and other considerations described in the [HHS Grants Policy Statement](#).

Pre-award costs are allowable only as described in the [HHS Grants Policy Statement](#).

Additional funding restrictions are listed below and will be part of the Notice of Award.

1. Prior to the purchase of any items of equipment (\$25,000 or more) the grantee must provide the Grants Management Specialist with a detailed justification and cost of the requested item for prior approval by the Grants Management Specialist and the Project Officer (PO).
2. The grantee must provide the Grants Management Specialist, in the following circumstances, with the specified documents prior to the actual start of any renovations (A&R) proposed for review and approval by both the Grants Management Specialist and the PO:

A&R less than \$50,000/year (not to exceed \$150,000 over 3 consecutive years)

- Provide the GMO with a detailed justification for the proposed A&R

A&R more than \$50,000/year (not to exceed \$150,000 over 3 consecutive years)

- Provide GMO requirements stated in Items I and II only (below)

A&R over \$75,000/year (not to exceed \$150,000 over 3 consecutive years)

- Provide GMO requirements stated in Items I, II, and III (below)

Two copies of the following documents must be submitted to the Grants Management Officer (GMO) either at the time of application or in postaward budgeting:

I. A single line drawing of existing space and proposed alterations.

II. A narrative description, including a statement of the proposed functional utilization of the space and equipment requirements. The description should include a reasonable detail and explanation of the need, character, and extent of the project's planned functions to be housed in the space proposed for A&R. The information submitted to the GMO should include but not necessarily be limited to the following:

- General information and purpose
- Description of the functions to be performed in the space.
- A space schedule (detailed description of floor space);
- A list of fixed equipment proposed for the facility.
- A cost estimate (see sample format attached)
- Description of special design problems.
- Description of the utility systems existing and proposed for the modified facility.
- Description of plans to provide accessibility for the physically handicapped (if applicable).
- Description of provision for the requirements of the Life Safety Code (if applicable)
- Statement of how long the property is leased (if applicable).
- Statement on other topics required by program legislation or regulations.
- Statement of which safety criteria will be met, including laboratory safety guidelines, animal care criteria, etc., as appropriate to explain the proposed design parameters.

III. If requested by the Center, either prior to or after approval of the application, grantees must submit a copy of architectural and engineering (Design Development and Final Design) documents including:

- The final project cost estimate.
- Coded architectural floor plans showing the final arrangement of space committed to the program.
- Final working drawings and specifications.
- The design analysis report, describing the heating, ventilation, and air conditioning system, plumbing system, and electrical power system.
- Provisions to meet the various mandatory Federal requirements and special clearances.

3. Funds may be used to pay student tuition, stipends, fellowships, etc.

## 7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. **Paper applications will not be accepted.**

**Applicants must complete all required registrations before the application due date.** [Section III. Eligibility Information](#) contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit [Applying Electronically](#). For assistance with application submission, contact the Application Submission Contacts in [Section VII](#).

### **Important reminders:**

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key

Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to FDA. See [Section III](#) of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See [more tips](#) for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the assigned Grants Management Specialist and responsiveness by [components of participating organizations](#), FDA. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed. ]

## Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in [NOT-OD-13-030](#).

# Section V. Application Review Information

## 1. Criteria

### Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit.

#### Significance (25 Points)

Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? ]

#### Investigator(s) (20 Points)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? ]

#### Innovation (20 Points)

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? ]

## **Approach (20 Points)**

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or FDA-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?

## **Environment (15 Points)**

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

## **Additional Review Criteria**

As applicable for the project proposed, reviewers will evaluate the following additional items, but will not give separate scores for these items and should not consider them in providing an overall score.

## **Protections for Human Subjects**

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

## **Inclusion of Women, Minorities, and Children**

When the proposed project involves human subjects and/or FDA-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

## **Vertebrate Animals**

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving

animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the [Worksheet for Review of the Vertebrate Animal Section](#).

### **Biohazards**

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

### **Resubmissions**

[Not Applicable ]

### **Renewals**

[For Renewals, the committee will consider the progress made in the last funding period. ]

### **Revisions**

[Not Applicable ]

### **Applications from Foreign Organizations**

[Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.]

### **Select Agent Research**

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

### **Resource Sharing Plans**

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) [Data Sharing Plan](#); (2) [Sharing Model Organisms](#); and (3) Genomic Data Sharing Plan ([GDS](#)).

### **Authentication of Key Biological and/or Chemical Resources:**

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

### **Budget and Period of Support**

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

## **2. Review and Selection Process**

Application will be evaluated for scientific and technical merit by an Objective Review Committee using the stated [review criteria](#).

As part of the objective review, all applications:

- Will receive a written critique.

[Appeal of objective review will not be accepted for the application submitted in response to this FOA.]

### **3. Anticipated Announcement and Award Dates**

Successful applicant will be notified of additional information that may be required or other actions leading to an award. The decision not to award a grant, or to award a grant at a particular funding level, is discretionary and is not subject to appeal to any FDA or HHS official or board.

## **Section VI. Award Administration Information**

### **1. Award Notices**

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for the successful application. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.

Awardees must comply with any funding restrictions described in [Section IV.5. Funding Restrictions](#). Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found in the [HHS Grants Policy Statement](#).

### **2. Administrative and National Policy Requirements**

All FDA grant and cooperative agreement awards include the [HHS Grants Policy Statement](#) as part of the NoA.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), FDA awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgment about the applicant's integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 "Federal awarding agency review of risk posed by applicants." This provision will apply to all FDA grants and cooperative agreements.

HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English

proficiency. Please see <http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html>. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see <http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html>; and <http://www.hhs.gov/ocr/civilrights/understanding/index.html>. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at <http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html> or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at <http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53>.

FDA considers the sharing of research resources developed through FDA-sponsored research an important means to enhance the value and further the advancement of research. When research resources have been developed with FDA funds and the associated research findings published, those findings must be made readily available to the scientific community.

Upon acceptance for publication, scientific researchers must submit the author's final manuscript of the peer-reviewed scientific publication resulting from research supported in whole or in part with FDA funds to the NIH National Library of Medicine's (NLM) PubMed Central (PMC). FDA defines the author's final manuscript as the final version accepted for journal publication, which includes all modifications from the publishing peer review process. The PMC archive is the designated repository for these manuscripts for use by the public, health care providers, educators, scientists, and FDA. Please see the FDA Public Access Policy.

Additional terms and conditions regarding FDA regulatory and CFSAN programmatic requirements may be part of the Notice of Award.

## **Cooperative Agreement Terms and Conditions of Award**

The following special terms of award are in addition to, and not in lieu of, otherwise applicable OMS administrative guidelines, HHS grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and FDA grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial FDA programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the FDA purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role of activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the FDA as defined below.

### **2. A.1. Principal Investigator Rights and Responsibilities**

The Principal Investigator will have the primary responsibility for and dominant role in planning, directing, and executing the proposed project, With the FDA staff being substantially involved as a partner with the PI.

Awardee will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and FDA policies.

### **2. A.2. FDA Responsibilities**

An FDA Project Officer will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:



The program project officer will monitor the grantee periodically. The monitoring may be in the form of telephone conversations, emails, quarterly reviews, or written correspondence between the project officer/grants management officer and the Principal Investigator. Periodic site visits with officials of the grantee organization may also occur. The results of these monitoring activities will be recorded in the official grant file and will be available to the grantee upon request, consistent with applicable disclosure statutes and with FDA disclosure regulations. Also, the grantee organization must comply with all special terms and conditions of the grant, including those that state that future funding will depend on recommendations from the project officer. In addition,

- a. FDA will have prior approval of the appointment of all key administrative and scientific personnel proposed by the grantee.
- b. FDA will be directly involved in the guidance and development of the program.

FDA scientists will participate, with the grantee, in determining and carrying out scientific and technical activities. Collaboration will also include data analysis, interpretation of findings and, where appropriate, co-authorship of publications. ]

### **3. Reporting**

When multiple years are involved, awardees will be required to submit the [Research Performance Progress Report \(RPPR\)](#) annually and financial statements as required in the Notice of Award.

A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the [HHS Grants Policy Statement](#).

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable FDA grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at [www.fsrs.gov](http://www.fsrs.gov) on all subawards over \$25,000.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than \$10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.

## **Section VII. Agency Contacts**

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

### **Application Submission Contacts**

eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post



submission issues)

Finding Help Online: <http://grants.nih.gov/support/> (preferred method of contact)

Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

[Grants.gov Customer Support](#) (Questions regarding Grants.gov registration and submission, downloading forms and application packages)

Contact Center Telephone: 800-518-4726

Web ticketing system: <https://grants-portal.psc.gov/ContactUs.aspx>

Email: [support@grants.gov](mailto:support@grants.gov)

### **Scientific/Research Contact(s)**

Eric Olson

Project Officer

Food and Drug Administration

Center for Food Safety and Applied Nutrition

5001 Campus Drive

CPK1, Rm. 4A-036, HFS 006

College Park, MD 20740

Telephone: 240-402-1674

E-mail: [eric.olson@fda.hhs.gov](mailto:eric.olson@fda.hhs.gov)

### **Objective Review Contact(s)**

Kiara Fowler

Office of Acquisitions & Grants Services (OAGS)

Food and Drug Administration

Telephone: 240-402-3099

Email: [Kiara.Fowler@fda.hhs.gov](mailto:Kiara.Fowler@fda.hhs.gov)

### **Financial/Grants Management Contact(s)**

Kiara Fowler

Office of Acquisitions & Grants Services (OAGS)

Food and Drug Administration

Telephone: 240-402-3099

Email: [Kiara.Fowler@fda.hhs.gov](mailto:Kiara.Fowler@fda.hhs.gov)

## **Section VIII. Other Information**

All awards are subject to the terms and conditions, cost principles, and other considerations described in the [HHS Grants Policy Statement](#).

### **Authority and Regulations**

Awards are made under the authorization of Section 301 of the Public Health Service Act (42 USC 241) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.